Research team to receive AACR Team Science Award

NewsGuard 100/100 Score

The fourth annual American Association for Cancer Research Team Science Award will be given to Dana-Farber/Harvard Cancer Center Thoracic Oncology Research Team at the AACR 101st Annual Meeting 2010. This research team is comprised of interdisciplinary investigators from the Dana-Farber Cancer Institute, Brigham and Women's Hospital, Massachusetts General Hospital, Beth Israel Deaconess Medical Center and Harvard Medical School.

The AACR Team Science Award recognizes an outstanding interdisciplinary research team for its innovative and meritorious science that has advanced or will likely advance cancer research, detection, diagnosis, prevention or treatment.

"We are incredibly pleased to honor the Dana-Farber/Harvard group with the AACR Team Science Award," said Margaret Foti, Ph.D., M.D. (h.c.), chief executive officer of the AACR. "This team has an interdisciplinary and inclusive approach to cancer research that epitomizes how cancer research will be conducted in the future. More than ever, investigators are collaborating on projects that expedite scientific breakthroughs and translate to clinical benefits from a number of different fields for patients."

Investigators from the Dana-Farber/Harvard Cancer Center Thoracic Oncology Research Team characterized the impact of genomic changes in epidermal growth factor receptor (EGFR) genes in lung cancer that led to a fundamental change in the treatment of patients with lung cancer. The team initially discovered the lung cancer-associated mutations in EGFR, assessed the origin and development of these mutations, and tested pharmacologic agents in prospective clinical trials of patients with genomically defined lung cancer.

The AACR Team Science Award, generously supported by a grant from Eli Lilly and Company, is given to affect change within the traditional cancer research culture by recognizing those individuals and institutions that value and foster interdisciplinary team science. The team will collectively receive a $50,000 prize. The Dana-Farber/Harvard Cancer Center Thoracic Oncology Research Team will also be cited for its leadership role in fostering team science.

Honorees from the Dana-Farber/Harvard Cancer Center Thoracic Oncology Research Team include:

•Michael J. Eck, M.D., Ph.D., professor of biological chemistry and molecular pharmacology, department of cancer biology, Dana-Farber Cancer Institute; and professor, department of biological chemistry and molecular pharmacology, Harvard Medical School;

•Jeffrey A. Engelman, M.D., Ph.D., assistant professor in medicine, Harvard Medical School; and chief of thoracic oncology, Massachusetts General Hospital Cancer Center;

•Nathanael S. Gray, Ph.D., assistant professor, department of biological chemistry and molecular pharmacology, Harvard Medical School; and assistant professor, cancer biology, Dana-Farber Cancer Institute;

•Daniel A. Haber, M.D., Ph.D., director, Massachusetts General Hospital Cancer Center; Isselbacher/Schwartz professor of oncology, Harvard Medical School; and investigator, Howard Hughes Medical Institute;

•Pasi A. Jänne, M.D., Ph.D., associate professor of medicine, Harvard Medical School; and director of the Translational Research Lab, Dana-Farber Cancer Institute;

•Bruce E. Johnson, M.D., professor of medicine, Harvard Medical School; director, Dana-Farber/Harvard Cancer Center Lung Cancer Program; and director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute;

•Susumu Kobayashi, M.D., Ph.D., assistant professor in medicine, Harvard Medical School and Beth Israel-Deaconess Medical Center;

•Eunice L. Kwak, M.D., Ph.D., instructor in medicine, Harvard Medical School, Massachusetts General Hospital Cancer Center;

•Neal I. Lindeman, M.D., assistant professor of pathology, Harvard Medical School; and associate pathologist, molecular diagnostics and clinical chemistry, Brigham and Women's Hospital;

•Thomas J. Lynch, M.D., professor of medicine and director, Yale Cancer Center; physician-in-chief, Smilow Cancer Hospital, New Haven, Conn.; former professor of medicine, Harvard Medical School; and former chief, division of hematology and oncology, Massachusetts General Hospital;

•Shyamala Maheswaran, Ph.D., associate professor of surgery, Massachusetts General Hospital Cancer Center;

•Matthew L. Meyerson, M.D., Ph.D., professor of pathology and director, Center for Cancer Genome Discovery, Dana-Farber Cancer Institute; and senior associate member, Broad Institute;

•Lecia V. Sequist, M.D., M.P.H., assistant professor in medicine, Harvard Medical School, Center for Thoracic Cancers, Massachusetts General Hospital;

•Jeffrey E. Settleman, Ph.D., professor, department of medicine, Harvard Medical School; and scientific director, Massachusetts General Hospital Cancer Center;

•Daniel G. Tenen, M.D., professor of medicine, Harvard Medical School and Beth Israel Deaconess Medical Center;

•Mehmet Toner, Ph.D., professor of surgery, Massachusetts General Hospital Laboratory for Bioengineering in Medicine;

•Kwok-Kin Wong, M.D., Ph.D., associate professor of medicine, Harvard Medical School and Dana-Farber Cancer Institute.

The AACR Team Science Award will be presented during the AACR 101st Annual Meeting 2010 opening ceremony on Sunday, April 18, from 8:15 a.m. until 9:30 a.m. ET, at the Walter E. Washington Convention Center.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Expanding research and clinical options for children with cancer